# Co-Diagnostics, Inc.: overview CODX · Nasdaq · CIK 1692415 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/codx.md) · [Financials](/companies/codx/financials.md) · [Filings](/companies/codx/filings.md) · [Insiders](/companies/codx/insiders.md) Latest reported revenue: [$166.1k](/filings/0001493152-26-037762.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037762). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [641](/filings/0001493152-25-022300.md) | [149 d](/filings/0001493152-26-014158.md) | [50.3](/filings/0001493152-26-023085.md) | [163](/filings/0001493152-26-037762.md) | [145](/filings/0001493152-25-022300.md) | [264 d](/filings/0001493152-26-014158.md) | [146](/filings/0001493152-26-023085.md) | [166](/filings/0001493152-26-037762.md) | | Gross margin | % | [53.6%](/filings/0001493152-25-022300.md) | [(70.8%) d](/filings/0001493152-26-014158.md) | [57.1%](/filings/0001493152-26-023085.md) | [80.3%](/filings/0001493152-26-037762.md) | [81.9%](/filings/0001493152-25-022300.md) | [46.0% d](/filings/0001493152-26-014158.md) | [(32.8%)](/filings/0001493152-26-023085.md) | [72.7%](/filings/0001493152-26-037762.md) | | Operating margin | % | [(1596.4%)](/filings/0001493152-25-022300.md) | [(7973.9%) d](/filings/0001493152-26-014158.md) | [(17009.7%)](/filings/0001493152-26-023085.md) | [(4946.1%)](/filings/0001493152-26-037762.md) | [(4824.5%)](/filings/0001493152-25-022300.md) | [(10056.7%) d](/filings/0001493152-26-014158.md) | [(6309.1%)](/filings/0001493152-26-023085.md) | [(3732.5%)](/filings/0001493152-26-037762.md) | | Net margin | % | [(1512.4%)](/filings/0001493152-25-022300.md) | [(7387.4%) d](/filings/0001493152-26-014158.md) | [(14983.5%)](/filings/0001493152-26-037762.md) | [(4745.0%)](/filings/0001493152-26-037762.md) | [(4049.3%)](/filings/0001493152-25-022300.md) | [(9755.1%) d](/filings/0001493152-26-014158.md) | [(6262.3%)](/filings/0001493152-26-037762.md) | [(3782.4%)](/filings/0001493152-26-037762.md) | | Diluted EPS | $ per share | [(0.32)](/filings/0001493152-25-022300.md) | not reported | [(7.05)](/filings/0001493152-26-023085.md) | [(7.00)](/filings/0001493152-26-037762.md) | [(0.16)](/filings/0001493152-25-022300.md) | not reported | [(4.06)](/filings/0001493152-26-023085.md) | [(1.46)](/filings/0001493152-26-037762.md) | | Free cash flow | $k | [(7,404) d](/filings/0001493152-25-022300.md) | [(8,304) d](/filings/0001493152-26-014158.md) | [(8,837)](/filings/0001493152-26-023085.md) | [(8,689) d](/filings/0001493152-26-037762.md) | [(5,980) d](/filings/0001493152-25-022300.md) | [(6,331) d](/filings/0001493152-26-014158.md) | [(7,988)](/filings/0001493152-26-023085.md) | [(7,171) d](/filings/0001493152-26-037762.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [97.9](/filings/0001493152-23-007925.md) | [34.2](/filings/0001493152-24-009955.md) | [6.8](/filings/0001641172-25-000932.md) | [3.9](/filings/0001493152-26-014158.md) | [0.6](/filings/0001493152-26-014158.md) | | Gross margin | % | [88.2%](/filings/0001493152-23-007925.md) | [84.0%](/filings/0001493152-24-009955.md) | [38.6%](/filings/0001641172-25-000932.md) | [74.5%](/filings/0001493152-26-014158.md) | [64.3%](/filings/0001493152-26-014158.md) | | Operating margin | % | [47.1%](/filings/0001493152-23-007925.md) | [(78.8%)](/filings/0001493152-24-009955.md) | [(626.9%)](/filings/0001641172-25-000932.md) | [(1023.7%)](/filings/0001493152-26-014158.md) | [(8058.8%)](/filings/0001493152-26-014158.md) | | Net margin | % | [37.5%](/filings/0001493152-23-007925.md) | [(41.6%)](/filings/0001493152-24-009955.md) | [(518.7%)](/filings/0001641172-25-000932.md) | [(961.4%)](/filings/0001493152-26-014158.md) | [(7533.6%)](/filings/0001493152-26-014158.md) | | Diluted EPS | $ per share | [1.23](/filings/0001493152-23-007925.md) | [(0.45)](/filings/0001493152-24-009955.md) | [(1.20)](/filings/0001641172-25-000932.md) | [(37.22)](/filings/0001493152-26-014158.md) | [(35.25)](/filings/0001493152-26-014158.md) | | Free cash flow | $m | [40.4](/filings/0001493152-23-007925.md) | [5.1](/filings/0001493152-24-009955.md) | [(23.4)](/filings/0001641172-25-000932.md) | [(29.9)](/filings/0001493152-26-014158.md) | [(29.8)](/filings/0001493152-26-014158.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/codx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $731.6k | 236,000 | | New +236,000 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $276.6k | 89,240 | | New +89,240 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $180.7k | 58,275 | | New +58,275 | | [Private Advisory Group LLC](/funds/1632965.md) | 2026-06-30 | $122.1k | 39,387 | | Reduced −2,000 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $99.2k | 31,995 | | New +31,995 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $96.8k | 31,239 | | New +31,239 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $79.3k | 25,575 | | New +25,575 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $61.3k | 19,776 | | Added +19,775 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $49.9k | 16,091 | | Added +8,723 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $45.9k | 14,800 | | New +14,800 | ## Recent filings [All 388 filings](/companies/codx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 16:15 ET | [8-K](/filings/0001493152-26-047242.md) | 5.07 Shareholder vote results | 0001493152-26-047242 | | 2026-10-15 | 06:10 ET | [8-K/A](/filings/0001493152-26-047089.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-047089 | | 2026-10-13 | 06:10 ET | [8-K](/filings/0001493152-26-046676.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-046676 | | 2026-10-05 | 19:38 ET | [8-K](/filings/0001493152-26-045652.md) | 5.07 Shareholder vote results | 0001493152-26-045652 | | 2026-09-25 | 16:45 ET | [8-K](/filings/0001493152-26-044346.md) | 5.07 Shareholder vote results | 0001493152-26-044346 | | 2026-09-16 | 10:30 ET | [8-K](/filings/0001493152-26-042854.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-042854 | | 2026-09-16 | 08:45 ET | [8-K](/filings/0001493152-26-042844.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-042844 | | 2026-09-15 | 16:05 ET | [8-K](/filings/0001493152-26-042744.md) | 8.01 Other events | 0001493152-26-042744 | | 2026-09-04 | 16:30 ET | [8-K](/filings/0001493152-26-041560.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-041560 | | 2026-09-04 | 09:00 ET | [8-K](/filings/0001493152-26-041468.md) | 5.07 Shareholder vote results | 0001493152-26-041468 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-014158.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ac65b686-14cc-4a2a-8aa2-7823dfee88a5) ## About the filer - CIK: 1692415 - Tickers: CODX - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: UT - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:01 ET. No prices; not investment advice.